Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Adamas Pharmaceuticals Inc's Business Segments
Adamas Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 26
Regions Reported
-
Adamas Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product94.9%
- Royalty5.1%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 25 | 94.9% |
| Royalty | $ 1 | 5.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Adamas Pharmaceuticals Inc
Adamas Pharmaceuticals is a specialty pharmaceutical company, based in Emeryville, California, that focuses on developing and commercializing drugs for the treatment of neurological and psychiatric disorders such as Parkinson's disease, multiple sclerosis, and dementia-related psychosis. The company was founded in 2000 by Gregory Went, Ph.D., a former biotechnology executive, and John Lloyd, a former chief medical officer of Clarity Medical Systems. The company's name "Adamas" comes from the Greek word that means "unbreakable", "unconquerable" or "diamond".
Adamas's main product is GOCOVRI (amantadine) extended-release capsules, the first and only FDA-approved medication specifically indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Dyskinesia is a common side effect of long-term treatment with levodopa, which causes involuntary and abnormal movement. GOCOVRI works by gradually releasing amantadine throughout the day, which reduces dyskinesia by modulating NMDA receptors in the brain. The drug was approved by the FDA in August 2017 and launched in January 2018.
Besides GOCOVRI, Adamas Pharmaceuticals has several other products in its pipeline. ADS-4101 is a modified-release version of amantadine that is being developed for the treatment of multiple sclerosis-related walking impairment. The drug is currently in Phase 3 clinical trials. In addition, the company is developing ADS-5102, an extended-release version of memantine, a drug used to treat dementia-related psychosis. The drug is currently in Phase 2 clinical trials.
Adamas Pharmaceuticals is also collaborating with several pharmaceutical companies to develop new drugs. The company has a partnership with Otsuka Pharmaceutical to develop a new drug candidate for the treatment of major depressive disorder, and a collaboration with Janssen Pharmaceuticals to develop a new drug candidate for the treatment of epilepsy. Overall, Adamas Pharmaceuticals is a promising specialty pharmaceutical company that has successfully developed and commercialized a novel drug for the treatment of dyskinesia in Parkinson's disease and has a strong pipeline of products for other neurological and psychiatric disorders.
Adamas's main product is GOCOVRI (amantadine) extended-release capsules, the first and only FDA-approved medication specifically indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Dyskinesia is a common side effect of long-term treatment with levodopa, which causes involuntary and abnormal movement. GOCOVRI works by gradually releasing amantadine throughout the day, which reduces dyskinesia by modulating NMDA receptors in the brain. The drug was approved by the FDA in August 2017 and launched in January 2018.
Besides GOCOVRI, Adamas Pharmaceuticals has several other products in its pipeline. ADS-4101 is a modified-release version of amantadine that is being developed for the treatment of multiple sclerosis-related walking impairment. The drug is currently in Phase 3 clinical trials. In addition, the company is developing ADS-5102, an extended-release version of memantine, a drug used to treat dementia-related psychosis. The drug is currently in Phase 2 clinical trials.
Adamas Pharmaceuticals is also collaborating with several pharmaceutical companies to develop new drugs. The company has a partnership with Otsuka Pharmaceutical to develop a new drug candidate for the treatment of major depressive disorder, and a collaboration with Janssen Pharmaceuticals to develop a new drug candidate for the treatment of epilepsy. Overall, Adamas Pharmaceuticals is a promising specialty pharmaceutical company that has successfully developed and commercialized a novel drug for the treatment of dyskinesia in Parkinson's disease and has a strong pipeline of products for other neurological and psychiatric disorders.
Adamas Pharmaceuticals Inc: Overview
Adamas Pharmaceuticals Inc is a biopharmaceutical company based in the United States, primarily focusing on the development and commercialization of innovative therapies tailored for neurological and psychiatric disorders. By concentrating on chronic conditions such as Parkinsons disease (PD) and multiple sclerosis (MS), the companys goal is to improve the quality of life for patients affected by these debilitating illnesses.
Segments
Adamas Pharmaceuticals Inc operates within a single segment—the development and commercialization of novel medications specifically targeted towards neurological and psychiatric disorders. This concentrated approach allows the company to focus its resources and expertise on understanding complex conditions that require specialized treatments, facilitating advances in therapeutic options for healthcare providers and patients alike.
Products
Adamas Pharmaceuticals Inc has developed and markets several key products that address specific symptoms associated with neurological and psychiatric disorders. These include:
1. GOCOVRI:
- Indication: GOCOVRI is recognized as the first and only FDA-approved medication specifically designed for treating dyskinesia in patients with PD who are receiving levodopa therapy.
- Mechanism: It helps regulate involuntary movements associated with the disease and also reduces offperiods, which are times when the medication effectiveness diminishes, causing significant challenges for patients.
- Dosage Form: GOCOVRI is available as an extended-release capsule, allowing for convenient once-daily dosing.
2. NAMZARIC:
- Indication: NAMZARIC serves as a treatment option for individuals with moderate to severe dementia due to Alzheimers disease.
- Composition: It combines two established medications—memantine, which helps with cognitive function, and donepezil, which works to manage symptoms associated with Alzheimers disease by enhancing neurotransmitter levels in the brain.
- Benefits: This combination aims to provide a synergistic effect, addressing memory loss and behavioral symptoms associated with Alzheimers disease.
3. ADS-4101:
- Indication: This product is a novel therapeutic agent targeted at treating partial-onset seizures in patients with epilepsy.
- Development Status: Currently, ADS-4101 is under investigation, but it aims to address the substantial unmet needs within the epilepsy treatment landscape, focusing on improving seizure control and patient quality of life.
4. ADS-5102:
- Indication: Designed for patients suffering from walking impairment due to MS, ADS-5102 is a once-daily, extended-release formulation of amantadine.
- Functionality: This medication enhances walking ability by addressing fatigue and other factors that hinder ambulation in patients with MS, promoting greater mobility and independence.
Services
Alongside its pharmaceutical offerings, Adamas Pharmaceuticals Inc provides a range of supportive services, ensuring healthcare professionals and patients have comprehensive resources available. These services include:
1. Clinical Development: Adamas facilitates and provides support for the clinical development of innovative therapies aimed at neurological and psychiatric disorders, ensuring research methodologies adhere to regulatory standards and patient safety protocols.
2. Medical Information: The company supplies a breadth of educational resources and medical information, with clinical data, publications, and research findings made accessible to both healthcare providers and patients. This knowledge-sharing helps promote informed treatment decisions.
3. Patient Support:
- Programs: Adamas offers a variety of patient-centered support options, including financial assistance programs to help alleviate the costs of medications, case management services to coordinate care, and educational resources focusing on disease management.
- Patient Navigation: These resources help patients navigate complex treatment regimens and understand their conditions better, contributing to better adherence and outcomes.
4. Healthcare Provider Support: Adamas Pharmaceuticals Inc is committed to equipping healthcare providers with the necessary tools to deliver optimal care. This includes providing clinical guidelines, educational materials, and reimbursement assistance, ensuring that practitioners can effectively manage treatment for patients with neurological and psychiatric challenges.
Conclusion
Adamas Pharmaceuticals Inc stands out as a dedicated biopharmaceutical entity focused on harnessing innovation to tackle the complexities of neurological and psychiatric disorders. Through its specialized products and comprehensive services, the company aims to create a significant impact on the lives of patients suffering from chronic conditions, ultimately striving for better health outcomes and enhanced quality of life.
Adamas Pharmaceuticals Inc is a biopharmaceutical company based in the United States, primarily focusing on the development and commercialization of innovative therapies tailored for neurological and psychiatric disorders. By concentrating on chronic conditions such as Parkinsons disease (PD) and multiple sclerosis (MS), the companys goal is to improve the quality of life for patients affected by these debilitating illnesses.
Segments
Adamas Pharmaceuticals Inc operates within a single segment—the development and commercialization of novel medications specifically targeted towards neurological and psychiatric disorders. This concentrated approach allows the company to focus its resources and expertise on understanding complex conditions that require specialized treatments, facilitating advances in therapeutic options for healthcare providers and patients alike.
Products
Adamas Pharmaceuticals Inc has developed and markets several key products that address specific symptoms associated with neurological and psychiatric disorders. These include:
1. GOCOVRI:
- Indication: GOCOVRI is recognized as the first and only FDA-approved medication specifically designed for treating dyskinesia in patients with PD who are receiving levodopa therapy.
- Mechanism: It helps regulate involuntary movements associated with the disease and also reduces offperiods, which are times when the medication effectiveness diminishes, causing significant challenges for patients.
- Dosage Form: GOCOVRI is available as an extended-release capsule, allowing for convenient once-daily dosing.
2. NAMZARIC:
- Indication: NAMZARIC serves as a treatment option for individuals with moderate to severe dementia due to Alzheimers disease.
- Composition: It combines two established medications—memantine, which helps with cognitive function, and donepezil, which works to manage symptoms associated with Alzheimers disease by enhancing neurotransmitter levels in the brain.
- Benefits: This combination aims to provide a synergistic effect, addressing memory loss and behavioral symptoms associated with Alzheimers disease.
3. ADS-4101:
- Indication: This product is a novel therapeutic agent targeted at treating partial-onset seizures in patients with epilepsy.
- Development Status: Currently, ADS-4101 is under investigation, but it aims to address the substantial unmet needs within the epilepsy treatment landscape, focusing on improving seizure control and patient quality of life.
4. ADS-5102:
- Indication: Designed for patients suffering from walking impairment due to MS, ADS-5102 is a once-daily, extended-release formulation of amantadine.
- Functionality: This medication enhances walking ability by addressing fatigue and other factors that hinder ambulation in patients with MS, promoting greater mobility and independence.
Services
Alongside its pharmaceutical offerings, Adamas Pharmaceuticals Inc provides a range of supportive services, ensuring healthcare professionals and patients have comprehensive resources available. These services include:
1. Clinical Development: Adamas facilitates and provides support for the clinical development of innovative therapies aimed at neurological and psychiatric disorders, ensuring research methodologies adhere to regulatory standards and patient safety protocols.
2. Medical Information: The company supplies a breadth of educational resources and medical information, with clinical data, publications, and research findings made accessible to both healthcare providers and patients. This knowledge-sharing helps promote informed treatment decisions.
3. Patient Support:
- Programs: Adamas offers a variety of patient-centered support options, including financial assistance programs to help alleviate the costs of medications, case management services to coordinate care, and educational resources focusing on disease management.
- Patient Navigation: These resources help patients navigate complex treatment regimens and understand their conditions better, contributing to better adherence and outcomes.
4. Healthcare Provider Support: Adamas Pharmaceuticals Inc is committed to equipping healthcare providers with the necessary tools to deliver optimal care. This includes providing clinical guidelines, educational materials, and reimbursement assistance, ensuring that practitioners can effectively manage treatment for patients with neurological and psychiatric challenges.
Conclusion
Adamas Pharmaceuticals Inc stands out as a dedicated biopharmaceutical entity focused on harnessing innovation to tackle the complexities of neurological and psychiatric disorders. Through its specialized products and comprehensive services, the company aims to create a significant impact on the lives of patients suffering from chronic conditions, ultimately striving for better health outcomes and enhanced quality of life.